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It remains a matter of speculation as to whether the sense CUG-containing RNA and/or the antisense
CAG-encoding polyglutamine peptide serves as the pathogenic moiety in Huntington’s disease like-2
(HDL2). In this issue of Neuron, Wilburn et al. show that in a HDL2 mouse model, the polyglutamine peptide
drives disease progression.Among the first microsatellite expansion
diseases identified 20 years ago was
the X-linked, CAG trinucleotide repeat
disorder spinobulbar muscular atrophy
(SBMA, or Kennedy’s disease) (La Spada
et al., 1991). In SBMA and eight additional
neurodegenerative diseases, the CAG
repeat is located within the open reading
frame and encodes a stretch of gluta-
mines (Orr and Zoghbi, 2007), providing
the basis for their designation as polyglut-
amine (polyQ) expansion disorders. The
most recent polyQ expansion disease
identified, SCA17, came to light 10 years
ago (Nakamura et al., 2001). However,
over the last decade, no additional neuro-
degenerative syndromes havequalified as
polyQ expansion diseases, although
others have been suggested as candi-
dates. Two in particular, SCA8 and Hun-
tington’s disease like-2 (HDL2), map to
loci containing an unstable CAG repeat.
SCA8 is a slowly progressive neurodegen-
erative disease arising from a CTG/CAG
expansion located on chromosome
13q21 (Koob et al., 1999), while HDL2 is
associated with a CTG/CAG repeat at
the Junctophilin-3 (JPH3) locus with the
CTG repeat on the JPH3 sense strand
(Holmes et al., 2001). It is important to
note that while the molecular mechanism
or mechanisms underlying the polyQ
diseases are a matter of considerable
investigation and discussion, a basic
tenant of the field is that the polyQ-con-
taining protein/peptide is the pathogenic
entity. However, to date there is biochem-
ical evidence only for the CUG-repeat-
containing transcript, and not the polyQ-
encoding transcript, in SCA8 and HDL2
in humans (Koob et al., 1999; Holmes
et al., 2001). Furthermore, the CUG-
containing RNA species can be as toxicas the polyQ peptide, as exemplified in
the myotonic dystrophies DM1 and
DM2 (Ranum and Cooper, 2006). As
such, the focus has been on whether the
CUG-containing strand, which encodes
a detectable RNA in SCA8 and HDL2, is
the pathogenic culprit. In fact, for both
SCA8 and HDL2, there is evidence to
suggest involvement of a toxic RNA
species in disease progression (Daugh-
ters et al., 2009; Rudnicki et al., 2007).
Yet, particularly for HDL2, there remains
a puzzling feature of its pathology, where
like those of HD, HDL2 brains contain
intranuclear inclusions that react with the
polyQ antibody 1C2 (Rudnicki et al.,
2008). The presence of polyQ-1C2-posi-
tive inclusions suggests that two mecha-
nismsmightcontribute todisease;a toxic -
RNA encoded by one strand and a polyQ
peptide encoded by the other (Figure 1).
In an attempt to clarify the molecular
source of pathogenicity in HDL2, Yang
and colleagues (as detailed in this issue
of Neuron) engineered a series of trans-
genic mice expressing human JPH3
mutant alleles. Using bacterial artificial
chromosomes (BACs), an approached
pioneered by the Yang group for the study
of HD, Wilburn et al. (2011) generated
transgenic mice carrying 165 kb from the
JPH3 locus with 120 CAG repeats.
These mutant JPH3 BAC mice presented
with several key features found in HDL2
patients. Among these are an age-depen-
dent motor deficit, forebrain atrophy, and
the presence of nuclear inclusions posi-
tive for ubiquitin and reactive with two
polyQ antibodies, including 1C2. At a
molecular level, Yang and colleagues
provide evidence for a novel promoter
that drives expression of a polyQ-encod-
ing transcript from the DNA strand in theNeuronantisense orientation to JPH3. Impor-
tantly, Wilburn et al. provide biochemical
evidence that mutant BAC-JPH3 brains
express insoluble polyQ peptides of
a size range that would be expected to
be encoded by the JPH3 CAG antisense
strand of the BAC transgene. However,
the nuclear inclusions in the mutant
BAC-JPH3 mice are also positive for
RNA from the sense CUG strand. Given
this finding, which of the two transcripts
is the pathogenic species in the BAC-
JPH3 mice? Does disease progression
require functional expression of both
transcripts?
To address the extent to which the
CAG-polyQ-encoding antisense tran-
script contributes to pathogenesis, Wil-
burn et al. developed a second version
of an expanded CAG repeat BAC-JPH3
transgenic mouse, designated BAC-
HDL2-STOP. In this mouse, exon 1 of
the JPH3 transgene was replaced with
a previously well-characterized transcrip-
tion STOP sequence such that expres-
sion of the JPH3 CUG sense strand is
selectively silenced while expression of
the antisense CAG transcript remains
intact. By behavioral and neurological
measures, the BAC-HDL2-STOP mice
expressing only the CAG antisense tran-
script develop motor deficits and degen-
erative pathology very similar to that
seen in the original BAC-JPH3 mice
expressing both transcripts. Although
the extent to which the JPH3 sense
CUG transcript contributes to disease
was not assessed directly, these results
provide strong evidence that the CAG
antisense transcript is very pathogenic
and a prominent contributor to disease
progression in this mouse model of
HDL2. In a final series of studies, Wilburn70, May 12, 2011 ª2011 Elsevier Inc. 377
Figure 1. The JPH3 Locus Indicating Bidirectional Transcription that
Generates aSenseCUGTranscript andanAntisensepolyQ-Encoding
CAG Transcript
The blocky gray arrows indicate transcription start sites. JPH3 exons and
introns are depicted with the CTG/CAG repeat located in alternatively spliced
exon 2a. Small gray boxes depict polyA addition sites. The transcriptional start
site for theCAG (antisense JPH3) transcript is positioned based on the results of
Wilburn et al. (2011).
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Previewset al. provide evidence that,
like other polyQ disorders
(e.g., HD, SCA3, and SBMA),
the nuclear inclusions in
mutant BAC-JPH3 mice and
HDL2 patients are positive
for the CREB binding protein
(CBP) and that CBP-medi-
ated transcription is disrup-
ted, extending the patho-
genic similarities betweenHD
and the BAC-JPH3 mice by
identifying a shared patho-
genic mechanism of tran-
scriptional dysfunction.
In sum, Wilburn et al.
present compelling evidence
that the phenotype of their
BAC-JPH3 mice meets the
two major criteria for classifi-
cation as a polyQ-basedneurodegenerative disease. Mutant BAC-
JPH3 mice express a biochemically
detectable polyQ peptide that is sufficient
to cause disease. Since pathogenicity of
the CUG-containing strand in absence of
a CAG transcript was not examined, these
studies do not rule out the possibility
that, in part, a toxic RNA from the sense
CUG strand may contribute to disease.
However, given the robust disease pheno-
type in the BAC-HDL2-STOP mice, its
seems very likely that if a CUG sense
RNA contributes to disease in this model,
it does so to a far lesser extent than the
antisense-encoded polyQ peptide.
Perhaps the more gripping question is
whether the work of Wilburn et al. is suffi-
cient to justify admission of HDL2 to the
group of human polyQ expansion neuro-
degenerative diseases. Without question,
the work of Wilburn et al. demonstrates
a very elegant murine genetic approach
for ascertaining the biological impact of
an antisense CAG transcript and provides
support for HDL2 being a polyQ disease.
Yet one absolutely crucial piece of data
remains elusive. On the one hand,Wilburn
et al. illustrate themany pathological simi-
larities between HDL2 and the polyQ
disease HD, including the presence of378 Neuron 70, May 12, 2011 ª2011 ElsevierpolyQ-1C2-positive nuclear inclusions in
the brains of HDL2 patients. However,
unlike as in HD, there is no direct evidence
in humans to suggest that the JPH3 anti-
sense CAG transcript is a stable RNA
transcript that encodes a polyQ peptide.
Wilburn et al. suggest several possible
reasons for the inability to detect either
the JPH3 antisense CAG transcript or
the polyQ protein. For example, they point
out that the inability to detect either the
JPH3 antisense CAG transcript or the
polyQ protein in HDL2 patient brains
might reflect the loss of neurons express-
ing them in the disease, a feature not seen
in the BAC-JPH3 mice. Nevertheless, the
fact remains that in HD patient brains,
a HD CAG transcript and huntingtin
protein are readily detectable. If HDL2
indeed shares a polyQ pathogenic mech-
anism with HD, why has it been difficult to
provide molecular evidence for JPH3
CAG/polyQ expression in humans? Given
the findings presented by Wilburn et al., it
is worth pursuing RNA sequencing
studies in human patient populations to
provide direct evidence of the wild-type
JPH3 antisense CAG transcript. In the
absence of such data, one needs to
keep in mind that the BAC-JPH3 modelInc.of HDL2 was generated using
a repeat size considerably
longer than that seen in
HDL2 patients (120 Qs versus
50 Qs, respectively). Accord-
ingly, it seems prudent to
recognize this caveat when
considering the relevance of
the mouse model to the
human disease. Nonetheless,
the work by Yang and
colleagues paves the way for
future studies aimed at ex-
tending the polyQ-mediated
mechanism of pathology to
humans with HDL2.REFERENCES
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